Study of an injection for geographic atrophy in AMD
Part of Eyes & vision clinical trials.
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years old or older.
- You have geographic atrophy caused by age-related macular degeneration (AMD).
- Your vision in the study eye is between 20/40 and 20/320 (or better than 20/200 for the second part of the study).
- The size of the GA lesion in your study eye is between 2.5 and 17.5 mm² (or 2.5 and 14.0 mm² for the second part).
- You have not had any treatment for wet AMD in the study eye, and you have not had gene therapy in either eye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
This study tests a new drug called STL303 for geographic atrophy, a condition where the back of the eye slowly loses cells, causing vision loss. The drug aims to slow or stop this vision loss in people over 60.
This study tests a new gene therapy that may slow or stop the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes vision loss. The treatment is given as an injection into the eye and aims to preserve remaining vision.
This study uses special eye imaging to look closely at areas of damage in the back of the eye (geographic atrophy) caused by age-related macular degeneration. It will help doctors understand early-stage disease better and may guide future treatments.
This study uses specialized eye imaging to track changes in geographic atrophy, a type of vision loss from macular degeneration. Researchers will use new imaging techniques to better understand how this condition progresses and how treatments work.
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
Hear when a new Geographic Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.